1. Home
  2. OUT vs PTCT Comparison

OUT vs PTCT Comparison

Compare OUT & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OUTFRONT Media Inc.

OUT

OUTFRONT Media Inc.

N/A

Current Price

$28.64

Market Cap

5.3B

Sector

Real Estate

ML Signal

N/A

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$67.57

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUT
PTCT
Founded
2013
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
6.0B
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
OUT
PTCT
Price
$28.64
$67.57
Analyst Decision
Strong Buy
Buy
Analyst Count
6
17
Target Price
$28.50
$80.65
AVG Volume (30 Days)
1.4M
750.5K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
3.94%
N/A
EPS Growth
N/A
264.48
EPS
0.54
0.90
Revenue
$1,831,700,000.00
$264,734,000.00
Revenue This Year
$6.19
N/A
Revenue Next Year
$3.08
$17.70
P/E Ratio
$53.35
$76.46
Revenue Growth
0.04
36.19
52 Week Low
$16.97
$57.74
52 Week High
$34.96
$90.87

Technical Indicators

Market Signals
Indicator
OUT
PTCT
Relative Strength Index (RSI) 31.11 37.58
Support Level $24.48 $67.57
Resistance Level $29.27 $70.01
Average True Range (ATR) 0.60 2.04
MACD -0.07 -0.12
Stochastic Oscillator 6.93 8.96

Price Performance

Historical Comparison
OUT
PTCT

About OUT OUTFRONT Media Inc.

Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: